Literature DB >> 29985186

Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis.

Paul J Thuluvath1,2, Steven Hanish1,2, Yulia Savva1,2.   

Abstract

BACKGROUND: Patients with nonalcoholic steatohepatitis (NASH) cirrhosis have excellent postliver transplant survival despite having many comorbidities. We hypothesized that this could be due to a selection bias.
METHODS: We analyzed the United Network for Organ Sharing data from 2002 to 2016 and compared postliver transplant survival of NASH (n = 7935) patients with cryptogenic cirrhosis (CC) (n = 6087), alcoholic cirrhosis (AC) (n = 16 810), and autoimmune hepatitis cirrhosis (AIH) (n = 2734).
RESULTS: By 3 years of listing, the cumulative incidence (CI) of death or deterioration was 29% for NASH, 28% for CC and AC, and 24% for AIH, but when adjusted for risk factors, the CI was similar for NASH and AIH. The factors that increased the risk of waiting list removal due to death/deterioration were poor performance status, encephalopathy, diabetes, high Model for End-stage Liver Disease, Hispanic race, older age and a low serum albumin. Most patients were transplanted within the first year (median, 2 months; interquartile range, 1-7 months) of listing and by 5 years, the unadjusted CI of transplantation was 54% for NASH, 52% for CC, 51% for AIH, and 48% for AC. The adjusted CI of transplantation within 2 months of listing was higher for AC (subhazard ratio [SHR], 1.17), AIH (SHR, 1.17), and CC (SHR, 1.13) when compared with NASH, but after 2 months, adjusted transplantation rates decreased in AC (SHR, 0.6), AIH (SHR, 0.78), and CC (SHR, 0.95). The negative predictors of receiving a transplant were dialysis, female sex, nonwhite race, high albumin, and creatinine.
CONCLUSIONS: Patients with NASH cirrhosis are not disadvantaged by higher waitlist removal or lower transplantation rates.

Entities:  

Mesh:

Year:  2019        PMID: 29985186     DOI: 10.1097/TP.0000000000002355

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age.

Authors:  Patrick McCabe; Artin Galoosian; Robert J Wong
Journal:  Dig Dis Sci       Date:  2019-10-22       Impact factor: 3.199

Review 2.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

3.  Functional Status at Liver Transplant Waitlisting Correlates With Greater Odds of Encephalopathy, Ascites, and Spontaneous Bacterial Peritonitis.

Authors:  Patrick McCabe; Grishma Hirode; Robert Wong
Journal:  J Clin Exp Hepatol       Date:  2020-04-27

4.  Living donor liver transplantation versus donation after brain death and donation after circulatory death liver transplantation in the US.

Authors:  Matthew Black; Amar Gupta; Sumeet K Asrani; Tsung-Wei Ma; Giuliano Testa; Anji Wall
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-03-09

Review 5.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .

Authors:  Naga Swetha Samji; Rajiv Heda; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05

Review 6.  Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge.

Authors:  Justin A Steggerda; Krishnaraj Mahendraraj; Tsuyoshi Todo; Mazen Noureddin
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

7.  Fatal intracardiac and pulmonary arterial thromboembolic damage following ABO-incompatible living donor liver transplantation for autoimmune hepatitis: A case report.

Authors:  Won Kyu Choi; Junghan Kim; Ho Joong Choi; Sang Hyun Hong; Min Suk Chae
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

8.  Sitagliptin Is More Effective Than Gliclazide in Preventing  Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease.

Authors:  Jing Ren; Xiaoyu Wang; Christine Yee; Mark D Gorrell; Susan V McLennan; Stephen M Twigg
Journal:  Molecules       Date:  2022-01-22       Impact factor: 4.411

9.  Mortality on the UNOS Waitlist for Patients with Autoimmune Liver Disease.

Authors:  Jaspreet S Suri; Christopher J Danford; Vilas Patwardhan; Alan Bonder
Journal:  J Clin Med       Date:  2020-01-23       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.